MEET THE TEAM
Watch: Get to know the DRTB-HDT project team!
The EU-funded DRTB-HDT project will determine if two adjunctive host-directed therapies can prevent the poor outcomes of treatment in cases of RIF-R TB.
Patients with RIF-R TB and other risk factors for poor outcome will participate in a randomised, controlled, three-armed multicentre trial.
WORLD TB MONTH 2024
Join us in commemorating World TB Month as we celebrate our collective strides towards ending TB.
“Host-directed adjunctive treatments (HDTs) have the potential to accelerate the eradication of MTB infection and promote the recovery of lung function by enhancing the microbicidal activity of phagocytic cells and by interrupting mechanisms of lung damage.” DRTB-HDT project Principal Investigator.
The European Union-funded DRTB-HDT project consortium is led by The Aurum Institute, with participating organisation’s, The Swiss Tropical and Public Health Institute, Ludwig-Maximilians-Universität München (Ludwig Maximilian University of Munich), The Research Center Borstel, The University of Antwerp, The Marius Nasta Institute of Pneumophthisiology (IPMN), The Phthisiopneumology Institute (IFP CD) of Chisinau, The Georgia National Center of Tuberculosis and Lung Diseases (NCTLD), The Instituto Nacional de Saúde – INS, Ministry of Health, Mozambique and The Wits Health Consortium.
Together, let’s champion innovation, collaboration, and progress as we strive to end TB.
DR TB- HDT team visits global CRS
Leading up to World TB Day 2024, The DRTB-HDT project team embarked on a journey with purpose in a site visit tour to project participating clinical trial sites, ensuring every step counts in the fight to End TB.
The team visited the following sites:
- The Aurum Institute – Tembisa
- Clinical HIV Research Unit (CRHU) King Dinuzulu – Durban
- CRHU Isango Lethemba – Port Elizaberth
- CHRU Themba Lethu – Johannesburg
- The Phthisiopneumology Institute (IFP CD) – Moldova
- The Georgia National Center of Tuberculosis and Lung Diseases (NCTLD) – Georgia
The purpose of the visit was to provide oversight of the clinical trials, ensuring their seamless operation, and to facilitate the incorporation of additional sites to bolster recruitment efforts.
This World TB Month let’s remember the importance of global initiatives like the EU-funded DRTB-HDT project. Together, we’re determined to make a difference and rewrite the narrative of treatment outcomes for RIF-R TB cases.
MycoTube 2024
2nd International Virtual Conference on Mycobacterium tuberculosis Research and Drug Development
Developers visit DRTB site
The Aurum Institute Tembisa Clinical Research Site as part of the DRTB-HDT trial hosted Medicines Development for Global Health (MDGH) and PDP Funders Group. MDGH are developers of Dovramilast, a compound used in the DRTB-HDT trial.
Consortium members are encouraged to share articles, activities and events with the Secretariat to be featured in this monthly update newsletter.